Acute Myelogenous Leukemia (Record no. 109769)
[ view plain ]
| 000 -LEADER | |
|---|---|
| fixed length control field | 03429nam a22004695i 4500 |
| 001 - CONTROL NUMBER | |
| control field | 978-0-387-69259-3 |
| 003 - CONTROL NUMBER IDENTIFIER | |
| control field | DE-He213 |
| 005 - DATE AND TIME OF LATEST TRANSACTION | |
| control field | 20140220084454.0 |
| 007 - PHYSICAL DESCRIPTION FIXED FIELD--GENERAL INFORMATION | |
| fixed length control field | cr nn 008mamaa |
| 008 - FIXED-LENGTH DATA ELEMENTS--GENERAL INFORMATION | |
| fixed length control field | 100715s2010 xxu| s |||| 0|eng d |
| 020 ## - INTERNATIONAL STANDARD BOOK NUMBER | |
| International Standard Book Number | 9780387692593 |
| -- | 978-0-387-69259-3 |
| 024 7# - OTHER STANDARD IDENTIFIER | |
| Standard number or code | 10.1007/978-0-387-69259-3 |
| Source of number or code | doi |
| 050 #4 - LIBRARY OF CONGRESS CALL NUMBER | |
| Classification number | RC254-282 |
| 072 #7 - SUBJECT CATEGORY CODE | |
| Subject category code | MJCL |
| Source | bicssc |
| 072 #7 - SUBJECT CATEGORY CODE | |
| Subject category code | MED062000 |
| Source | bisacsh |
| 082 04 - DEWEY DECIMAL CLASSIFICATION NUMBER | |
| Classification number | 616.994 |
| Edition number | 23 |
| 100 1# - MAIN ENTRY--PERSONAL NAME | |
| Personal name | Nagarajan, Lalitha. |
| Relator term | editor. |
| 245 10 - TITLE STATEMENT | |
| Title | Acute Myelogenous Leukemia |
| Medium | [electronic resource] : |
| Remainder of title | Genetics, Biology and Therapy / |
| Statement of responsibility, etc | edited by Lalitha Nagarajan. |
| 250 ## - EDITION STATEMENT | |
| Edition statement | 1. |
| 264 #1 - | |
| -- | New York, NY : |
| -- | Springer New York, |
| -- | 2010. |
| 300 ## - PHYSICAL DESCRIPTION | |
| Extent | IX, 280 p. |
| Other physical details | online resource. |
| 336 ## - | |
| -- | text |
| -- | txt |
| -- | rdacontent |
| 337 ## - | |
| -- | computer |
| -- | c |
| -- | rdamedia |
| 338 ## - | |
| -- | online resource |
| -- | cr |
| -- | rdacarrier |
| 347 ## - | |
| -- | text file |
| -- | |
| -- | rda |
| 490 1# - SERIES STATEMENT | |
| Series statement | Cancer Treatment and Research, |
| International Standard Serial Number | 0927-3042 ; |
| Volume number/sequential designation | 145 |
| 505 0# - FORMATTED CONTENTS NOTE | |
| Formatted contents note | The Leukemia Stem Cell -- Epigenetic Mechanisms in AML – A Target for Therapy -- Chromosomal Translocations in AML: Detection and Prognostic Significance -- Chromosomal Deletions in AML -- Genes Predictive of Outcome and Novel Molecular Classification Schemes in Adult Acute Myeloid Leukemia -- Receptor Tyrosine Kinase Alterations in AML – Biology and Therapy -- Lineage-Specific Transcription Factor Aberrations in AML -- Proleukemic RUNX1 and CBF? Mutations in the Pathogenesis of Acute Leukemia -- Acute Myeloid Leukemia with Mutated Nucleophosmin (NPM1): Molecular, Pathological, and Clinical Features -- MicroRNAs: New Players in AML Pathogenesis -- Murine Models of Human Acute Myeloid Leukemia -- Apoptosis in Leukemias: Regulation and Therapeutic Targeting -- Acute Promyelocytic Leukemia: A Paradigm for Differentiation Therapy -- Immunotherapy of AML -- Therapy of Acute Myelogenous Leukemia in Adults. |
| 520 ## - SUMMARY, ETC. | |
| Summary, etc | Acute myelogenous leukemia (AML), is the most common form of leukemia in adults. AML is a deadly form of malignancy, the prognosis for which has not improved in the last two decades. More importantly, it is a malignancy that is seen in older adults, therefore the number of cases is likely to rise as the population ages. Over the past 15 years, genetic mechanisms underlying AML have begun to unfold. Additional research in this area has helped identify key components and characteristics. Consequently, targeted therapy of AML is receiving much attention. It is the hope of researchers that as with chronic myelogenous leukemia (CML), and the drug, Gleevec, a targeted therapy for AML will be discovered. "The effective treatment of acute myelogenous leukemia remains a great challenge. This text reviews our understanding of the molecular and biologic basis of the disease. Leading investigators address advances in prognostication and therapeutic strategies that have significant promise." Steven T. Rosen, M.D. Series Editor |
| 650 #0 - SUBJECT ADDED ENTRY--TOPICAL TERM | |
| Topical term or geographic name as entry element | Medicine. |
| 650 #0 - SUBJECT ADDED ENTRY--TOPICAL TERM | |
| Topical term or geographic name as entry element | Hematology. |
| 650 #0 - SUBJECT ADDED ENTRY--TOPICAL TERM | |
| Topical term or geographic name as entry element | Oncology. |
| 650 14 - SUBJECT ADDED ENTRY--TOPICAL TERM | |
| Topical term or geographic name as entry element | Medicine & Public Health. |
| 650 24 - SUBJECT ADDED ENTRY--TOPICAL TERM | |
| Topical term or geographic name as entry element | Oncology. |
| 650 24 - SUBJECT ADDED ENTRY--TOPICAL TERM | |
| Topical term or geographic name as entry element | Hematology. |
| 710 2# - ADDED ENTRY--CORPORATE NAME | |
| Corporate name or jurisdiction name as entry element | SpringerLink (Online service) |
| 773 0# - HOST ITEM ENTRY | |
| Title | Springer eBooks |
| 776 08 - ADDITIONAL PHYSICAL FORM ENTRY | |
| Display text | Printed edition: |
| International Standard Book Number | 9780387692579 |
| 830 #0 - SERIES ADDED ENTRY--UNIFORM TITLE | |
| Uniform title | Cancer Treatment and Research, |
| -- | 0927-3042 ; |
| Volume number/sequential designation | 145 |
| 856 40 - ELECTRONIC LOCATION AND ACCESS | |
| Uniform Resource Identifier | http://dx.doi.org/10.1007/978-0-387-69259-3 |
| 912 ## - | |
| -- | ZDB-2-SME |
No items available.